L. Shepherd

发表

Correction note: Poisson point process models solve the “pseudo-absence problem” for presence-only data in ecology

D. Warton, L. Shepherd, 2010, 1011.3319.

Predictive Value of Prostate Specific Antigen in a European HIV-positive Cohort: Does One Size Fit All?

A. Mocroft, O. Kirk, J. Lundgren, 2016, Antiviral therapy.

Poor Linkage to Care Despite Significant Improvement in Access to Early cART in Central Poland – Data from Test and Keep in Care (TAK) Project

A. Mocroft, A. Horban, E. Firląg-Burkacka, 2016, PloS one.

Sterne, J. A. C. (2020). Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort

J. Sterne, P. Reiss, M. Gill, 2020 .

Cause‐specific mortality after diagnosis of cancer among HIV‐positive patients: A collaborative analysis of cohort studies

J. Sterne, A. d’Arminio Monforte, P. Reiss, 2020, International journal of cancer.

Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study.

A. Mocroft, V. Martel-Laferrière, M. Battegay, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cessation of cigarette smoking and the impact on cancer incidence in HIV-positive persons : The D : A : D Study

A. Mocroft, R. Weber, C. Sabin, 2018 .

Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus–infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

C. Leen, A. Mocroft, O. Kirk, 2017, HIV medicine.

Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

A. Mocroft, O. Kirk, J. Lundgren, 2015, HIV medicine.

Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations

A. Mocroft, O. Kirk, J. Lundgren, 2018, AIDS.

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

J. Sterne, F. Lampe, T. Sterling, 2017, The lancet. HIV.

Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study

A. Mocroft, O. Kirk, D. Raben, 2021, HIV research & clinical practice.

Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015

A. Mocroft, O. Kirk, A. Blaxhult, 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people

A. Mocroft, J. Lundgren, J. Weber, 2018, HIV medicine.

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

C. Morrison, F. Brun-Vézinet, F. Dabis, 2017, The Journal of antimicrobial chemotherapy.

Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy

J. Sterne, A. d’Arminio Monforte, F. Lampe, 2016, PloS one.

Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study

J. Sterne, A. d’Arminio Monforte, P. Reiss, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Castagna, A. Mocroft, O. Kirk, 2016, HIV medicine.

Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy: The D:A:D Study

C. Sabin, H. Furrer, P. Reiss, 2015, Journal of acquired immune deficiency syndromes.

CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)

J. Sterne, P. Reiss, T. Sterling, 2017, Clinical Infectious Diseases.

Cancer risk and use of PI or NNRTI-based combination antiretroviral therapy (cART): The D:A:D Study

C. Sabin, A. Phillips, P. Reiss, 2013 .

Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation

J. Sterne, J. Miro, P. Reiss, 2018, Journal of the International AIDS Society.

Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma